All Stories

  1. Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation
  2. Clinical nurse specialist role in setting up a joint hepatocellular carcinoma clinic at a specialist liver unit
  3. Hepatitis C treatment in primary care in regional australia
  4. Benefit of haemostatic spray in variceal bleeding: early application of spray or early application of guidelines?
  5. Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial
  6. The Royal Free Hospital ‘hub-and-spoke network model’ delivers effective care and increased access to liver transplantation
  7. What is the role of the microcirculation in liver disease
  8. Correction: Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy
  9. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites
  10. Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity
  11. Liver Transplantation
  12. Development and validation of a mathematical equation to estimate glomerular filtration rate in cirrhosis: The royal free hospital cirrhosis glomerular filtration rate
  13. Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices
  14. Randomized Controlled Trials to Define Viral Load Thresholds for Cytomegalovirus Pre-Emptive Therapy
  15. Elevated liver enzymes in inflammatory bowel disease
  16. Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade
  17. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score
  18. A la Carte Treatment of Acute Variceal Bleeding
  19. Consensus Statements: Management of the Acute Bleeding Episode
  20. Prevalence of significant liver disease in human immunodeficiency virus-infected patients exposed to Didanosine: A cross sectional study
  21. Selection criteria for resection in hepatocellular carcinoma: Can we expand them?
  22. Liver transplantation for acute liver failure because of genotype 3 hepatitis E virus infection
  23. Individualized care for portal hypertension: Not quite yet
  24. Synchronous Hepatic Epithelioid Hemangioendothelioma and Hepatocellular Carcinoma
  25. Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
  26. Adrenal insufficiency
  27. Lack of agreement for defining ‘clinical suspicion of rejection’ in liver transplantation: a model to select candidates for liver biopsy
  28. Beneficial Effect of Intra-Operative Methylprednisolone on Immediate post Liver Transplant Intensive Care Course
  29. Therapeutic hypothermia in acute liver failure: Not that hot?
  30. Inflammation-based scores do not predict post-transplant recurrence of hepatocellular carcinoma in patients within milan criteria
  31. De novouse of generic tacrolimus in liver transplantation - a single center experience with one-yr follow-up
  32. Inflammation-based scores and hepatocellular carcinoma - authors' reply
  33. Characteristics of Epstein-Barr viraemia in adult liver transplant patients: A retrospective cohort study
  34. Letter: prognostic scores in alcoholic hepatitis - authors' reply
  35. Generic tacrolimus in solid organ transplantation
  36. Endoprosthetics for bleeding esophageal varices
  37. Transient residence of a seropositive organ is sufficient to transfer human cytomegalovirus to a seronegative recipient
  38. Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort
  39. Anti-tumour necrosis factor agent and liver injury: Literature review, recommendations for management
  40. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma
  41. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma
  42. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
  43. Using an ‘action set’ for the management of acute upper gastrointestinal bleeding
  44. Erratum to: “Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation” [J Hepatol 2013;58:962–968]
  45. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer
  46. Liver transplantation for HIV/HCV coinfection: where is the controversy?
  47. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation
  48. Transarterial chemoembolisation is not superior to embolisation alone: The recent European Association for the Study of the Liver (EASL)–European Organisation for Research and Treatment of Cancer (EORTC) guidelines
  49. Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma
  50. A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma
  51. Early tacrolimus exposure after liver transplantation: Relationship with moderate/severe acute rejection and long-term outcome
  52. Transarterial therapies for hepatocellular carcinoma (HCC): A long way towards standardization
  53. Resource implications of expanding the use of donation after circulatory determination of death in liver transplantation
  54. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation
  55. Liver and pancreatic transplantation
  56. Cytomegalovirus Replication Kinetics in Solid Organ Transplant Recipients Managed by Preemptive Therapy
  57. Comparison of the sequential organ failure assessment score with the King's College Hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure
  58. Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count
  59. Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
  60. Critical Illness-Related Corticosteroid Insufficiency in Patients With Cirrhosis and Variceal Bleeding
  61. Hepatic Transplantation
  62. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial
  63. Anaesthesia for caesarean section in a patient with Budd–Chiari syndrome and hepatopulmonary syndrome post liver transplantation
  64. Increased bilirubin following fluid resuscitation with albumin: mechanisms behind an important observation
  65. Assessment of adrenocortical reserve in stable patients with cirrhosis
  66. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C Virus 1 year after liver transplantation
  67. Neurogenic diabetes insipidus presenting in a patient with subacute liver failure: a case report
  68. Fulminant Hepatic Failure: Treatment
  69. Severe, Acute Liver Injury and Khat Leaves
  70. Critically Ill Patients With Cirrhosis and Low Serum Sodium
  71. A self-expanding metal stent for complicated variceal hemorrhage: experience at a single center
  72. Generation of functional CD8+ T Cells by human dendritic cells expressing glypican-3 epitopes
  73. Primary biliary cirrhosis after liver transplantation: Influence of immunosuppression and human leukocyte antigen locus disparity
  74. Use of thromboelastography PlateletMapping™ to monitor antithrombotic therapy in a patient with Budd-Chiari syndrome
  75. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy
  76. A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation
  77. RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit
  78. Response
  79. Cirrhotics admitted to intensive care unit: the impact of acute renal failure on mortality
  80. Inhibition of major histocompatibility complex Class I antigen presentation by hepatitis C virus core protein in myeloid dendritic cells
  81. Recurrent bacteremia due to retained embolized glue following variceal obliteration
  82. Predictors of early rebleeding and mortality after acute variceal hemorrhage in patients with cirrhosis
  83. Significant small-bowel lesions detected by alternative diagnostic modalities after negative capsule endoscopy
  84. Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient
  85. A removable covered self-expanding metal stent for the management of Sengstaken-Blakemore tube–induced esophageal tear and variceal hemorrhage
  86. Clinical outcome of HCV-related graft cirrhosis and prognostic value of hepatic venous pressure gradient
  87. Prognostic models in cirrhotics admitted to intensive care units better predict outcome when assessed at 48 h after admission
  88. False-Positive Presentation of Battle’s Sign During Hepatic Encephalopathy
  89. Incidence of adrenal dysfunction in cirrhosis
  90. Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy
  91. Adrenal insufficiency in liver disease – What is the evidence?
  92. Prognostic impact of lactate in acute liver failure
  93. The role of infection and inflammation in the pathogenesis of hepatic encephalopathy and cerebral edema in acute liver failure
  94. Acute Liver Failure
  95. Associated Systemic Conditions
  96. Current management of the hepatorenal syndrome
  97. Progression of collagenous colitis to Crohn??s disease
  98. RE: El-Banayosy A, Kizner, L, Shcueler V, Bergmeier S, Dobaugh D, Koerfer R: First use of molecular adsorbent recirculation system technique in patients with hypoxic liver failure after cardiogenic shock. ASAIO J 50; 332???337, 2004.
  99. The role of the immune system in the control of hepatocellular carcinoma
  100. Management of Cirrhosis and Ascites
  101. Alcoholic hepatitis---the case for intensive management
  102. MYCOPHENOLATE MOFETIL MONOTHERAPY IN STABLE LIVER TRANSPLANT PATIENTS WITH CYCLOSPORINE-INDUCED RENAL IMPAIRMENT